Congress Members Urged Protection for Drug Imports
A group of 71 lawmakers requested that federal agencies preserve the ability for Americans to import prescription medicines.
Updated on Oct. 2, 2026 in Immigration
Live Poll
Should federal agencies prioritize drug import access even if it limits stricter international mail screening?
Seventy-one members of Congress signed a letter asking federal agencies to ensure continued access to personal-use prescription drug imports. The lawmakers expressed concern that upcoming Customs and Border Protection procedures for international mail could block access to licensed foreign pharmacies.
Why it matters
Lawmakers are pushing to prevent disruptions to affordable medication access for approximately 2.3 million Americans who rely on foreign-sourced prescriptions. The letter highlights a tension between security screening and the needs of patients who use international mail to obtain lower-cost drugs.
The letter was signed by 71 members of Congress who are requesting a delay in the implementation of new customs procedures. This action impacts an estimated 2.3 million Americans who rely on non-controlled prescription medicines from outside the country.
The players
Mark Pocan
Mark Pocan is a Democratic member of the United States House of Representatives representing Wisconsin's 2nd congressional district.
Jan Schakowsky
Jan Schakowsky is a Democratic member of the United States House of Representatives who has represented Illinois's 9th congressional district since 1999.
Customs and Border Protection
Customs and Border Protection is the federal law enforcement agency tasked with regulating and facilitating international trade and travel.
The details
The CBP is implementing a new process for international mail shipments designed to identify and intercept high-risk packages. Lawmakers have asked the HHS, DHS, FDA, and CBP to provide assurances that these procedures will not result in the routine refusal of personal-use medicines obtained from licensed foreign pharmacies.
Timeline
October 22, 2026: New CBP procedures for international mail are scheduled to take effect.
Political Context
This effort follows a pattern set by the FDA's personal importation policy by challenging federal regulatory enforcement regarding drug imports. Lawmakers opposing the move argue that security measures should not inadvertently penalize patients seeking lower-cost options abroad.
If the new customs procedures proceed without modification, patients who rely on international mail for prescriptions may face shipment delays or confiscation of their medicine. Readers should monitor whether federal agencies delay the new rules to provide specific accommodations for personal-use imports.
The takeaway
Patients who rely on imported medications should keep documentation of their prescriptions and consult with pharmacy providers as border procedures evolve. Ensuring clear communication between federal oversight agencies and the public remains a central priority for lawmakers addressing these drug access concerns.
Further reading
For more information on national border policies and procedures, visit the Immigration section.
Source note: This article includes information reported by Urban Milwaukee.
Live Poll
Should federal agencies prioritize drug import access even if it limits stricter international mail screening?
